BT3.F Lineage Cell Therapeutics Inc
- Market cap
- EUR 246M
- P/E
- -
- P/B
- 4.37x
- ROE
- -10.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BT3.F undervalued?
Graham numberThe Graham number of Lineage Cell Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lineage Cell Therapeutics Inc fundamental analysis
No fundamental analysis for Lineage Cell Therapeutics Inc yet.
Lineage Cell Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter …
Full company profileLineage Cell Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lineage Cell Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.92M | 3.46M | 4.99M | 3.52M | 773K | 3.90M | 14.7M | 8.95M | 9.50M | 14.6M | 5.59M |
| Gross Profit | 5.57M | 3.29M | 4.69M | 3.10M | 388K | 2.47M | 14.0M | 8.27M | 9.17M | 14.4M | 5.59M |
| Operating Income | -59.0M | -40.7M | -41.0M | -38.9M | -26.4M | -49.2M | -22.5M | -24.7M | -21.5M | -21.8M | -33.0M |
| EBITDA | - | -37.4M | -37.7M | -35.7M | -24.4M | -48.3M | -21.8M | -24.0M | -20.9M | -21.1M | -32.3M |
| Net Income | 33.6M | -20.0M | -46.0M | -11.7M | -20.6M | -43.0M | -26.3M | -21.5M | -18.6M | -63.5M | -6.66M |
| EPS | - | -0.16 | -0.36 | -0.08 | -0.13 | -0.25 | -0.15 | -0.12 | -0.08 | -0.26 | -0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 143M | 173M | 102M | 125M | 108M | 175M | 124M | 101M | 113M | 113M | 106M |
| Total Liabilities | 12.1M | 8.98M | 9.41M | 14.2M | 12.8M | 83.6M | 51.7M | 39.0M | 36.2M | 69.2M | 46.4M |
| Shareholders' Equity | 118M | 163M | 93.8M | 113M | 96.2M | 92.2M | 73.3M | 63.4M | 78.4M | 44.5M | 60.9M |
| Cash & Short-term Investments | 22.1M | 36.8M | 23.6M | 9.50M | 32.6M | 55.7M | 11.4M | 35.4M | 45.8M | 40.8M | 37.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -42.3M | -30.5M | -30.9M | -31.9M | -19.8M | -23.6M | 1.06M | -28.6M | -23.1M | -18.9M | -30.6M |
| Capital Expenditure | 2.53M | 1.33M | 1.42M | 440K | 64.0K | 340K | 413K | 674K | 565K | 522K | 326K |
| Free Cash Flow | - | -31.8M | -34.2M | -32.4M | -19.8M | -23.9M | 646K | -29.2M | -23.7M | -19.4M | -31.0M |
| Ratios | |||||||||||
| ROE | 28.5% | -12.3% | -49.0% | -10.4% | -21.5% | -46.6% | -35.8% | -33.9% | -23.7% | -142.6% | -10.9% |
| ROA | 23.5% | -11.5% | -45.2% | -9.3% | -19.1% | -24.6% | -21.2% | -21.3% | -16.4% | -56.4% | -6.3% |
| Net Profit Margin | 566.8% | -577.7% | -922.0% | -333.1% | -2,671.3% | -1,104.2% | -178.7% | -240.2% | -195.9% | -436.5% | -119.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Lineage Cell Therapeutics Inc dividends
Lineage Cell Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:3 on Nov 25, 2019.
Who owns Lineage Cell Therapeutics Inc
- Insiders 4.86%
- Institutions 48.61%
- Public & others 46.53%
- Shares outstanding 253M
- Free float 191M
Lineage Cell Therapeutics Inc company profile
- Company name
- Lineage Cell Therapeutics Inc
- Ticker
- BT3.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Metals & Mining
- Employees
- 72
- Fiscal year end
- December
- Address
- 2173 Salk Avenue, Carlsbad, CA, United States, 92008
- Phone
- 442 287 8990
- Website
- lineagecell.com
About Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Lineage Cell Therapeutics Inc management
9- Mr. Brian M. Culley M.A., M.B.A.CEO, President & Director · born 1971
- Ms. Jill Ann HoweChief Financial Officer · born 1976
- Mr. George A. Samuel III, J.D.General Counsel & Company Secretary · born 1981
- Ms. Ioana C. HoneDirector of Investor Relations
- Dr. Charlotte Hubbert Ph.D.Vice President of Corporate Strategy & Development
- Dr. Priyantha Herath M.D., Ph.D.Senior VP & Head of Clinical Operations
- Dr. Rami Skaliter M.Sc., Ph.D.Chief Executive Officer of Cell Cure Neurosciences · born 1958
- Ms. Alexandra HernandezSenior Director of Finance & Controller
- Dr. Harold D. Waitz Ph.D.Vice President of Regulatory Affairs & Quality Control · born 1942